Jefferies Keeps Optimer (OPTR) at Buy as CEO Makes Plans For Growth

Article Related Press Releases (1) Related Articles (1) Stock Quotes (1) Comments (0)

Jefferies maintained a Buy rating on Optimer Pharmaceuticals (NASDAQ: OPTR), a company that focuses on the discovery, development and commercialization of anti-infective products, with one marketed drug for the treatment of diarrhea, DIFICID (fidaxomicin/OPT-80).

"While preannounced 3Q12 gross Dificid sales of $18.4M (~+2% q/q) are soft, OPTR's new strategy to drive further Dificid growth is reassuring," said analyst Eun K. Yang.

To address Dificid cost issues and enable patient access, Optimer Pharmaceuticals CEO offered a new strategy, including a 25 percent discount to acute care hospitals, New Technology Add-On Payment, and a Dificid Rx Assist program.

Jefferies cut its price target on Optimer to $16.00 (from $17.00) to reflect revised U.S. sales and EU royalties.

For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.

Shares of Optimer Pharmaceuticals closed at $11.46 yesterday, with a 52 week range of $10.00-$16.49.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Citi Raises PT on Micron Technology (MU) to $19
• Brinson Patrick Starts Vical (VICL) at Market Outperform
• Deutsche Bank Starts IHS Inc. (IHS) at Hold

Create E-mail Alert Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?